Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA
Joseph P. Garay(Scripps Research Institute), James E. Korkola(Oregon Health & Science University), Darcie Babcock(Oregon Health & Science University), Joe W. Gray(University of Newcastle Australia), Koei Chin(Oregon Health & Science University), Wallace Thompson(Oregon Health & Science University), Kaylyn L. Devlin(Oregon Health & Science University), Shanta Boddapati(Oregon Health & Science University), Moqing Liu(Oregon Health & Science University), Daniel P. Hollern(University of North Carolina at Chapel Hill), Spencer S. Watson(University Hospital of Lausanne), Laura M. Heiser(Oregon Health & Science University), Rebecca Smith(Oregon Health & Science University), Amanda Esch(Oregon Health & Science University), Tiera Liby(Oregon Health & Science University), Ting Zheng(Beijing Institute of Technology), Sunjong Kwon(Oregon Health & Science University)
Cited by 21
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China
|JAMA|2004|1.4k
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|614
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
|Journal of Clinical Investigation|2012|595